Preliminary Study of Peel Force and Discomfort of Removal of Adhesive Barriers in Normal and Peristomal Skin

NCT02003404 | Completed Results

• 2 other identifiers: 5642-OLUHSC IRB #: 205654091813
• Study Type: observational
• Target: 17
• Locations: 1 country
• Sites: 1

Brief Summary

This purpose of this study is to look at three commercially available ostomy barriers on peristomal (around the stoma) skin. Repeated barrier application and removal over years causes changes to the skin that the investigators wish to investigate. The primary objective is to measure peel force on normal skin and peel force on peristomal skin, with the intent of determining if differences occur. The study hypotheses is that no differences exist.

Conditions

Dermatologic Complications

Keywords

ostomy appliance

Outcome Measures

Primary Outcomes (1)

• Skin Barrier Peel Force

  Peel force of barrier materials, comparing peristomal skin to abdominal skin. A portable peel force analyser, previously validated, was used in the clinic to measure peel at 90 degrees to the plane of the body. Peel force was measured on peristomal skin and ipsilateral abdominal skin in the same subject.

  4 hours

Study Arms (2)

Control Abdominal Skin

Apply SoftFlex (standard wear commercial skin barrier), FlexWear (standard wear commercial skin barrier), and FlexTend (extended wear commercial skin barrier), material to non-peristomal abdominal skin.

Device: Control Abdominal Skin

Peristomal Abdominal Skin

Apply SoftFlex, FlexWear and FlexTend barrier material to peristomal abdominal skin.

Device: Peristomal Abdominal Skin

Interventions

Control Abdominal Skin DEVICE

Three barrier materials will be peeled from abdominal skin after a set period at a set rate.

Also known as: SoftFlex, FlexWear, FlexTend

Control Abdominal Skin

Peristomal Abdominal Skin DEVICE

Three barrier materials will be peeled from abdominal skin after a set period at a set rate.

Also known as: SoftFlex, FlexWear, FlexTend

Peristomal Abdominal Skin

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Ostomates with a normal peristomal skin and normal ipsilateral abdominal skin

You may qualify if:

• Colostomy, Ileostomy, or Urostomy patients at least 6 months post-surgery
• Males or females, age 18 to 80 years old at the time of enrollment
• Body Mass Index (BMI) between 18 and 50
• Willing to have two approximately 5" x 5" areas of the abdomen trimmed with a surgical clipper -- one in a ring around the stoma, and one on the opposite side
• Willing to remain within the testing room for the duration of the study
• Willing to allow a third person in the room as a witness for the duration of the study
• Able to position oneself onto and off of the examining table without the assistance of the Investigator
• Willing to refrain from vigorous exercise for the duration of the study
• Willing to not take any anti-inflammatory medications (except for Tylenol/acetaminophen) starting 48 hours prior to the study and for the duration of the study
• Willing to bring an extra barrier and replace their barrier worn during the study.
• Willing to follow the protocol as demonstrated by signing the Informed Consent Form
• In the opinion of the Investigator or qualified site personnel is qualified to participate

You may not qualify if:

• Clinically significant diseases, which may or may not be confined to the testing site, that may contraindicate participation; including but not limited to psoriasis, eczema, atopic dermatitis, and active cancer
• Use of topical drugs on the application site within 1 month.
• Use of lotions, creams, powders or oils on the application site in the 24 hours prior to application
• Pregnancy, lactation or planning a pregnancy as determined by interview only
• Other medical conditions, for example uncontrolled diabetes, which in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk
• Participation in any clinical test either using the abdomen as a test site or using systemic therapy within the previous thirty days
• Damaged skin or other skin conditions in or near test sites which includes sunburn, scars, numerous moles or other disfiguration of the test site
• Significant adipose tissue at the test site that would preclude adequate adhesion of the study devices
• Known allergy to any of the test materials

Sponsors & Collaborators

• Hollister Incorporated: lead
• Loyola University: collaborator

Study Sites (1)

La Grange Center for Health

La Grange Park, Illinois, 60526, United States

Location

Limitations and Caveats

Small sample size may not be generalizable to the population.

Results Point of Contact

• Title: Dr James Swan, MD
• Organization: Loyola University of Chicago

jswan@lumc.edu

708-485-1271

Study Officials

• James Swan, MD

  Loyola University

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 20, 2013
• First Posted: December 6, 2013
• Study Start: November 1, 2013
• Primary Completion: February 1, 2014
• Study Completion: February 1, 2014
• Last Updated: November 11, 2016
• Results First Posted: October 19, 2015

Record last verified: 2016-10

Locations

US (1)